HC Wainwright Has Pessimistic View of MIST Q1 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Stock analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.18) per share for the quarter, down from their prior forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q2 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at ($0.02) EPS.

Milestone Pharmaceuticals Stock Down 2.6 %

Shares of NASDAQ:MIST opened at $1.90 on Thursday. The firm has a market capitalization of $101.37 million, a PE ratio of -2.35 and a beta of 1.83. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $2.75. The firm has a fifty day moving average of $2.01 and a 200 day moving average of $1.82.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MIST. Jones Financial Companies Lllp raised its holdings in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after buying an additional 10,000 shares in the last quarter. National Bank of Canada FI grew its position in Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after acquiring an additional 11,600 shares during the last quarter. PVG Asset Management Corp purchased a new position in shares of Milestone Pharmaceuticals during the third quarter worth approximately $46,000. Atria Investments Inc lifted its holdings in shares of Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 4th quarter valued at $73,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.